KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $204.3 million.

  • Biomarin Pharmaceutical's Prepaid Assets rose 20.68% to $204.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year increase of 20.68%. This contributed to the annual value of $201.5 million for FY2024, which is 42.54% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Prepaid Assets stood at $204.3 million, which was up 15.28% from $177.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Prepaid Assets' 5-year high stood at $224.8 million during Q3 2023, with a 5-year trough of $91.2 million in Q1 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Prepaid Assets averaged around $180.9 million, with its median value being $177.2 million (2025).
  • In the last 5 years, Biomarin Pharmaceutical's Prepaid Assets tumbled by 41.44% in 2021 and then skyrocketed by 50.02% in 2023.
  • Biomarin Pharmaceutical's Prepaid Assets (Quarterly) stood at $110.4 million in 2021, then fell by 5.36% to $104.5 million in 2022, then skyrocketed by 35.28% to $141.4 million in 2023, then spiked by 42.54% to $201.5 million in 2024, then increased by 20.68% to $204.3 million in 2025.
  • Its Prepaid Assets stands at $204.3 million for Q3 2025, versus $177.2 million for Q2 2025 and $181.5 million for Q1 2025.